BioNano Genomics (BNGO) AI Stock Analysis

• Market Cap: $11.44M
• Dividend Yield: N/A
• Average Volume (3M): 74.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.61
• Revenue Growth: -24.04%
• EPS Growth: 84.11%
• Country: US
• Employees: 98
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 3,364,000
• 10 Day Avg. Volume: 95,101
• 30 Day Avg. Volume: 74,964
• PEG Ratio: -2.55
• Price to Book (P/B): 101.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -197.75
• Enterprise Value/Market Cap: 2.22K
• Enterprise Value/Revenue: 196.21
• Enterprise Value/Gross Profit: 26.40K
• Enterprise Value/Ebitda: -53.41
• 1Y Price Target: $9.00
• Price Target Upside: 167.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 41 Neutral
• Price Target: $3.00 ▼(-10.98%Downside)

BioNano Genomics is facing significant financial and operational challenges. The most impactful factor is the company's weak financial performance, marked by declining revenues and high leverage, which significantly affects the overall score. Technical indicators suggest bearish momentum, and valuation metrics indicate distress. While there are signs of operational improvements from the strategic shift, global trade uncertainties add to the risks.

Positive Factors

Market Adoption

A key driver is optical genome mapping gaining traction at leading institutions, seeing real-world use, and generating publications.

Reimbursement Advances

With a second CPT code now in place, integration into diagnostic workflows at leading institutions, and a continuing flow of publications, the company is well-positioned to drive further adoption and grow revenues.

Strategic Refocusing

Management has taken several steps to get itself back on track, including significant cost reductions, refocusing on its core optical genome mapping business, shifting focus from customer acquisition to expanding utilization, and securing runway into 1Q26.

Negative Factors

Market Challenges

It has been a challenging operating environment for research-oriented life science tools companies, and especially so for small caps.

Revenue Guidance

Bionano lowered its 2025 revenue guidance to factor in global trade and uncertainty.

Share Price Performance

The share price decline during the past 12 months was primarily due to the financing overhang.

BioNano Genomics Business Overview & Revenue Model

Company Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

How the Company Makes Money

BioNano Genomics makes money primarily through the sale and leasing of its Saphyr system, a cutting-edge platform for optical genome mapping. The company generates revenue from the sale of consumables and reagents used with the Saphyr system, which are necessary for conducting genomic experiments. Additionally, BNGO offers software solutions and services that support the analysis and interpretation of genomic data. The company also engages in partnerships and collaborations with research institutions and commercial entities, which can contribute to its revenue through joint development projects and shared research initiatives.

BioNano Genomics Financial Statement Overview

Summary

BioNano Genomics faces significant financial challenges with declining revenues, high leverage, and ongoing losses. The company's cash flow situation highlights a critical need for improved cost management and revenue generation to achieve financial stability.

Income Statement

BioNano Genomics has shown a declining revenue trend with a negative revenue growth rate from the previous year. The company exhibits poor profitability with a significantly negative net profit margin and EBIT margin, indicating ongoing losses. Gross profit margin is also low, underscoring cost management challenges.

Balance Sheet

The debt-to-equity ratio has increased, suggesting higher leverage, which poses a financial risk. The equity ratio remains moderate, but the consistent increase in liabilities relative to equity is concerning. Return on equity is not meaningful due to sustained losses.

Cash Flow

Operating and free cash flows are negative, indicating cash burn. The free cash flow to net income ratio highlights inefficiencies in converting net income to cash. However, investing and financing cash flows show some ability to secure funds, though not sufficiently covering losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.46M	30.78M	36.12M	27.80M	17.98M	8.50M
Gross Profit	960.00K	380.00K	9.57M	5.95M	3.87M	2.77M
EBITDA	-77.30M	-97.47M	-213.60M	-120.31M	-73.86M	-37.08M
Net Income	-83.70M	-112.02M	-232.49M	-132.60M	-72.44M	-41.14M
Balance Sheet
Total Assets	78.41M	76.67M	214.40M	307.50M	377.10M	60.45M
Cash, Cash Equivalents and Short-Term Investments	3.63M	9.47M	66.77M	113.19M	250.61M	38.45M
Total Debt	18.41M	27.30M	79.41M	11.67M	10.70M	16.33M
Total Liabilities	30.23M	41.30M	118.25M	58.10M	39.98M	25.37M
Stockholders Equity	48.19M	35.38M	96.16M	249.40M	337.12M	35.08M
Cash Flow
Free Cash Flow	-43.63M	-69.03M	-126.87M	-128.12M	-73.39M	-38.31M
Operating Cash Flow	-43.55M	-68.92M	-125.18M	-124.82M	-71.93M	-38.31M
Investing Cash Flow	12.19M	73.84M	24.16M	82.77M	-278.06M	-2.45M
Financing Cash Flow	18.82M	-13.69M	113.81M	23.01M	336.11M	61.90M

BioNano Genomics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNGO, the sentiment is Negative. The current price of 3.37 is below the 20-day moving average (MA) of 3.45, below the 50-day MA of 3.70, and below the 200-day MA of 10.03, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 43.63 is Neutral, neither overbought nor oversold. The STOCH value of 60.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNGO.

BioNano Genomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INBS	62 Neutral	$12.65M	―	-126.34%	―	3.87%	91.76%
ENZB	60 Neutral	$35.81M	―	-13.95%	―	―	―
Sector *	49 Neutral	AU$2.49B	4.37	-64.25%	2.83%	36.51%	13.14%
BNR	48 Neutral	$34.76M	―	-37.15%	―	-0.26%	60.09%
BIAF	42 Neutral	$8.25M	―	-290.85%	―	78.40%	22.41%
BNGO	41 Neutral	$11.44M	―	-127.82%	―	-24.04%	84.11%
MYNZ	41 Neutral	$5.46M	―	-809.29%	―	―	―

BioNano Genomics Corporate Events

BioNano Genomics Enhances Governance with New Appointment

On June 10, 2025, BioNano Genomics appointed Kristiina Vuori, M.D., Ph.D., to its Audit Committee, enhancing its governance structure. During the company’s 2025 Annual Meeting of Stockholders on June 11, 2025, key decisions included the election of Class I Directors, approval of executive compensation, ratification of BDO USA, P.C. as the independent accounting firm, and approval of the issuance of shares upon exercise of purchase warrants, reflecting active shareholder engagement and strategic alignment with Nasdaq requirements.

The most recent analyst rating on (BNGO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioNano Genomics stock, see the BNGO Stock Forecast page.